MedPath

IFN-gamma-releasing Assay Based Approach in Patients With Suspected Tuberculous Peritonitis

Not Applicable
Terminated
Conditions
Suspected Tuberculous Peritonitis
Interventions
Other: Blood and Ascites ELISPOT
Registration Number
NCT02175134
Lead Sponsor
Asan Medical Center
Brief Summary

The diagnosis of tuberculous peritonitis (TBP) is still challenging, and largely dependent on invasive procedures such as laparoscopy. A recently developed RD-1 gene-based assay for diagnosing TBP shows has given promising results. The investigators thus created a 2-step algorithm using the Blood/Ascites ELISPOT assays and adenosine deaminase (ADA) in ascites for differentiation of TBP from other diagnoses (Blood ELISPOT ≥6 spots or ADA ≥ 21 U/L' as a rule-out test and 'Ascites/Blood ratio ≥3' as a rule-in test). This study is the randomized controlled trial on whether this 2-step algorithm-based approach can reduce the laparoscopic biopsy for the diagnosis of TBP in patients with suspected TBP.

Detailed Description

Not available

Recruitment & Eligibility

Status
TERMINATED
Sex
All
Target Recruitment
2
Inclusion Criteria
  • all patients with suspected tuberculous peritonitis
  • age 16 or more
  • formal informed consent
Exclusion Criteria
  • not specified

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
two-step algorithm-based approachBlood and Ascites ELISPOTPerform the laparoscopic biopsy as a discretion of attending physician's decision, but if the below conditions are met, do not perform the laparoscopic biopsy. 1. Blood ELISPOT \>= 6 spots or ascites adenosine deaminase \> 20 IU/L, and 2. Ascites ELISPOT/Blood ELISPOT rato \> 3
Primary Outcome Measures
NameTimeMethod
the frequency of laparoscopic biopsy1 week after the enrollment
Secondary Outcome Measures
NameTimeMethod
the frequency of correct or wrong diagnosis6 months after the enrollment

the frequency of correct or wrong diagnosis

Trial Locations

Locations (1)

Asan Medical Center

🇰🇷

Seoul, Korea, Republic of

© Copyright 2025. All Rights Reserved by MedPath